☆ 4.7 Meeting Abstract

Establishment of a Predictive Model of GvHD-Free, Relapse-Free Survival after Allogeneic Hematopoietic Stem Cell Transplantation Using a Machine Learning Algorithm

BLOOD (2019)

Journal

BLOOD

Volume 134, Issue -, Pages -

Publisher

AMER SOC HEMATOLOGY

DOI: 10.1182/blood-2019-123241

Keywords

-

Categories

Hematology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Article Urology & Nephrology

Chronic kidney disease, survival and graft-versus-host-disease-free/relapse-free survival in recipients of allogeneic hematopoietic stem cell transplant

Karyne Pelletier, Gabrielle Cote, Kayla Madsen, Shiyi Chen, S. Joseph Kim, Christopher T. Chan, Jonas Mattsson, Ivan Pasic, Abhijat Kitchlu

Summary: Chronic kidney disease (CKD) adversely affects the long-term prognosis for allogeneic hematopoietic stem cell transplant (HSCT) recipients, leading to increased mortality risk and worse graft-versus-host-disease (GVHD)-free/relapse-free survival.

CLINICAL KIDNEY JOURNAL (2022)

Add to Collection

Article Hematology

Establishment of a predictive model for GVHD-free, relapse-free survival after allogeneic HSCT using ensemble learning

Makoto Iwasaki, Junya Kanda, Yasuyuki Arai, Tadakazu Kondo, Takayuki Ishikawa, Yasunori Ueda, Kazunori Imada, Takashi Akasaka, Akihito Yonezawa, Kazuhiro Yago, Masaharu Nohgawa, Naoyuki Anzai, Toshinori Moriguchi, Toshiyuki Kitano, Mitsuru Itoh, Nobuyoshi Arima, Tomoharu Takeoka, Mitsumasa Watanabe, Hirokazu Hirata, Kosuke Asagoe, Isao Miyatsuka, Le My An, Masanori Miyanishi, Akifumi Takaori-Kondo

Summary: This study developed a novel predictive model using a stacked ensemble of multiple machine-learning algorithms to achieve better risk stratification for GRFS. The results indicated lower probability of GRFS in the high-risk group compared to the low-risk group.

BLOOD ADVANCES (2022)

Add to Collection

Article Hematology

Feasibility of allogeneic hematopoietic stem cell transplantation in advanced age

Sara Fernandez-Luis, David Gomez Lamas, Juan Manuel Cerezo Martin, Juan Manuel Mora Barrios, Lucrecia Yanez San Segundo, Miriam Sanchez Escamilla, Noemi Fernandez-Escalada, Jose Alvaro Calvo Sanchez, Sergio Fernandez Garcia, Juan Jose Dominguez-Garcia, Mercedes Colorado Araujo, Monica Lopez-Duarte, Guillermo Martin-Sanchez, Andres Insunza Gaminde, Jose Inigo Romon Alonso, Rocio Lobeira Rubio, Jose Luis Arroyo Rodriguez, Beatriz Rueda Ciller, Mar Hermosilla Fernandez, Victor Marco Betes, Enrique Maria Ocio, Arancha Bermudez Rodriguez

Summary: This study analyzed the outcome of 97 patients older than 60 years who underwent their first allogeneic transplantation. The results showed that there were no significant differences in overall survival, progression-free survival, cumulative incidence of relapse, or non-relapse mortality between different age groups or conditioning regimens. The study suggests that older adults can safely and effectively undergo allogeneic transplantation with proper patient selection and individualized procedures.

ANNALS OF HEMATOLOGY (2023)

Add to Collection

Article Multidisciplinary Sciences

Impact of anti-thymocyte globulin on survival outcomes in female-to-male allogeneic hematopoietic stem cell transplantation

Masaharu Tamaki, Yu Akahoshi, Masahiro Ashizawa, Yukiko Misaki, Satoshi Koi, Sung-Won Kim, Yukiyasu Ozawa, Shin-ichiro Fujiwara, Shinichi Kako, Ken-ichi Matsuoka, Masashi Sawa, Yuta Katayama, Makoto Onizuka, Yoshinobu Kanda, Takahiro Fukuda, Yoshiko Atsuta, Kimikazu Yakushijin, Hideki Nakasone

Summary: Allogeneic hematopoietic cell transplantation between female donors and male recipients is a known risk factor for inferior survival outcomes. This study found that the use of anti-thymocyte globulin (ATG) in female-to-male allo-HCT did not reduce the risk of graft-versus-host disease (GVHD), but was associated with improved overall survival and decreased non-relapse mortality. The use of ATG in female-to-male allo-HCT resulted in survival outcomes similar to those in male-to-male allo-HCT, suggesting that ATG may overcome the inferiority of survival outcomes in female-to-male allo-HCT.

SCIENTIFIC REPORTS (2023)

Add to Collection

Article Biochemistry & Molecular Biology

The Benefits of the Post-Transplant Cyclophosphamide in Both Haploidentical and Mismatched Unrelated Donor Setting in Allogeneic Stem Cells Transplantation

Jaroslaw Dybko, Malgorzata Sobczyk-Kruszelnicka, Sebastian Makuch, Siddarth Agrawal, Krzysztof Dudek, Sebatian Giebel, Lidia Gil

Summary: This study compared the outcomes of patients who received post-transplant cyclophosphamide (PTCy) or conventional immunosuppressants after allogeneic hematopoietic cell transplantation. The study found that patients receiving PTCy had lower rates of acute graft-versus-host disease and cytomegalovirus reactivation, and higher survival rates. Further research with a larger sample size is needed to confirm these results.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Add to Collection

Article Hematology

Weight-based mycophenolate mofetil dosing predicts acute GVHD and relapse after allogeneic hematopoietic cell transplantation

Nelli Bejanyan, John Rogosheske, Qing Cao, Aleksandr Lazaryan, Shernan Holtan, Celalettin Ustun, Pamala Jacobson, Margaret MacMillan, Daniel J. Weisdorf, John Wagner, Mukta Arora, Claudio G. Brunstein

Summary: Higher weight-based MMF dose can reduce the risk of acute GVHD after allogeneic hematopoietic cell transplantation, but may increase the risk of relapse. This dose had no significant impact on engraftment, chronic GVHD, or survival. Prospective studies are needed to optimize MMF dosing after HCT.

EUROPEAN JOURNAL OF HAEMATOLOGY (2021)

Add to Collection

Review Immunology

The Role of Immune Checkpoint Molecules for Relapse After Allogeneic Hematopoietic Cell Transplantation

Natalie Kohler, Dietrich Alexander Ruess, Rebecca Kesselring, Robert Zeiser

Summary: Immune checkpoint molecules play a crucial role in relapse and treatment after allo-HCT by inhibiting the graft-versus-leukemia effect, allowing tumor cells to escape. The activation of inhibitory receptors on T cell surfaces by immune checkpoint molecules facilitates immune escape. Research shows that immune checkpoint blockade holds potential value in improving the immunotherapeutic effect of relapse after allo-HCT.

FRONTIERS IN IMMUNOLOGY (2021)

Add to Collection

Review Immunology

The impact of epigenetic modifications on allogeneic hematopoietic stem cell transplantation

Yiouli P. Ktena, Margarita Dionysiou, Lukasz P. Gondek, Kenneth R. Cooke

Summary: Epigenetics studies the regulation of gene expression without altering the DNA sequence. It plays a vital role in cellular homeostasis, differentiation, hematopoiesis, and immunity. Epigenetic modifications can be heritable and reversible, and there is growing interest in their potential role in allogeneic hematopoietic transplantation. This review provides an overview of epigenetic modifications and their functions, focusing on hematopoiesis and immunity in the context of allogeneic hematopoietic stem cell transplantation.

FRONTIERS IN IMMUNOLOGY (2023)

Add to Collection

Article Medicine, General & Internal

Evaluation of Ruxolitinib for Steroid-Refractory Chronic Graft-vs-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation

Hengwei Wu, Jimin Shi, Yi Luo, Yamin Tan, Mingming Zhang, Xiaoyu Lai, Jian Yu, Lizhen Liu, Huarui Fu, He Huang, Yanmin Zhao

Summary: In this study, the clinical response to ruxolitinib in patients with steroid-refractory chronic graft-vs-host disease after allogeneic hematopoietic stem cell transplantation was investigated, and its safety profile was evaluated during the treatment course. The majority of patients treated with ruxolitinib showed significant treatment responses with a relatively well-tolerated safety profile, with lung involvement and matched related donors being associated with less favorable treatment response.

JAMA NETWORK OPEN (2021)

Add to Collection

Review Oncology

The prevention of disease relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia

Enrico Maffini, Margherita Ursi, Francesco Barbato, Michele Dicataldo, Marcello Roberto, Elena Campanini, Elisa Dan, Francesco De Felice, Serena De Matteis, Gianluca Storci, Massimiliano Bonafe, Mario Arpinati, Francesca Bonifazi

Summary: Disease relapse post hematopoietic cell transplantation remains a major challenge, with novel cellular and biological therapies showing promise in treating acute leukemia relapse. Understanding the pathobiology of leukemia relapse is crucial for developing new therapeutic strategies, including targeted therapies and novel drug combinations.

FRONTIERS IN ONCOLOGY (2022)

Add to Collection

Review Immunology

How to improve the outcomes of elderly acute myeloid leukemia patients through allogeneic hematopoietic stem cell transplantation

Shan Jiang, Han Yan, Xuan Lu, Ruowen Wei, Haoran Chen, Ao Zhang, Wei Shi, Linghui Xia

Summary: In recent years, haploidentical transplantation technology has advanced, leading to increased availability of donors and improved conditions for elderly AML patients to receive allogeneic hematopoietic stem cell transplantation. This article summarizes the pre-transplant assessment methods, various sources of donors, conditioning regimens, and post-transplant complication management based on large-scale clinical studies.

FRONTIERS IN IMMUNOLOGY (2023)

Add to Collection

Article Hematology

Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia

Matthew J. Wieduwilt, Leland Metheny, Mei-Jie Zhang, Hai-Lin Wang, Noel Estrada-Merly, David Marks, A. Samer Al-Homsi, Lori Muffly, Nelson Chao, David Rizzieri, Robert Peter Gale, Shahinaz M. Gadalla, Mitchell Cairo, Alberto Mussetti, Steven Gore, Vijaya Raj Bhatt, Sagar S. Patel, Fotios Michelis, Yoshihiro Inamoto, Sherif M. Badawy, Edward Copelan, Neil Palmisiano, Mohamed A. Kharfan-Dabaja, Hillard M. Lazarus, Siddhartha Ganguly, Christopher Bredeson, Miguel Angel Diaz Perez, Ryan Cassaday, Bipin N. Savani, Karen Ballen, Rodrigo Martino, Baldeep Wirk, Ulrike Bacher, Mahmoud Aljurf, Asad Bashey, Hemant S. Murthy, Jean A. Yared, Ibrahim Aldoss, Nosha Farhadfar, Hongtao Liu, Hisham Abdel-Azim, Edmund K. Waller, Melhem Solh, Matthew D. Seftel, Marjolein van der Poel, Michael R. Grunwald, Jane L. Liesveld, Rammurti T. Kamble, Joseph McGuirk, Reinhold Munker, Jean-Yves Cahn, Jong Wook Lee, Cesar O. Freytes, Maxwell M. Krem, Lena E. Winestone, Usama Gergis, Sunita Nathan, Richard F. Olsson, Leo F. Verdonck, Akshay Sharma, Olle Ringden, Brian D. Friend, Jan Cerny, Hannah Choe, Saurabh Chhabra, Taiga Nishihori, Sachiko Seo, Biju George, Lee Ann Baxter-Lowe, Gerhard C. Hildebrandt, Marcos de Lima, Mark Litzow, Partow Kebriaei, Christopher S. Hourigan, Muhammad Bilal Abid, Daniel J. Weisdorf, Wael Saber

Summary: This study compared the outcomes of haploidentical hematopoietic cell transplantation (HCT) using posttransplant cyclophosphamide (PTCy) with other HCT approaches for acute lymphoblastic leukemia (ALL) patients. The results showed that haploidentical HCT using PTCy had similar overall survival (OS) but lower incidence of chronic graft-versus-host disease (cGVHD) compared to traditional matched sibling and unrelated donor HCT methods, making it a preferred alternative donor option for ALL patients in complete remission.

BLOOD ADVANCES (2022)

Add to Collection

Article Oncology

Community health status and outcomes after allogeneic hematopoietic cell transplantation in the United States

Sanghee Hong, Ruta Brazauskas, Kyle M. Hebert, Siddhartha Ganguly, Hisham Abdel-Azim, Miguel Angel Diaz, Sara Beattie, Stefan O. Ciurea, David Szwajcer, Sherif M. Badawy, Alois A. Gratwohl, Charles LeMaistre, Mahmoud D. S. M. Aljurf, Richard F. Olsson, Neel S. Bhatt, Nosha Farhadfar, Jean A. Yared, Ayami Yoshimi, Sachiko Seo, Usama Gergis, Amer M. Beitinjaneh, Akshay Sharma, Hillard Lazarus, Jason Law, Matthew Ulrickson, Hasan Hashem, Helene Schoemans, Jan Cerny, David Rizzieri, Bipin N. Savani, Rammurti T. Kamble, Bronwen E. Shaw, Nandita Khera, William A. Wood, Shahrukh Hashmi, Theresa Hahn, Stephanie J. Lee, J. Douglas Rizzo, Navneet S. Majhail, Wael Saber

Summary: This study analyzed the impact of community health status on allogeneic HCT outcomes using data from CHRR and CIBMTR, finding that patients residing in counties with a worse community health status have inferior survival due to increased risk of NRM after allogeneic HCT. There was no significant association between the community health status of the transplant center location and allogeneic HCT outcomes.

CANCER (2021)

Add to Collection

Article Immunology

Case Report: Combination Therapy With PD-1 Blockade for Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation Resulted in Fatal GVHD

Sun Yao, Chen Jianlin, Qiao Zhuoqing, Li Yuhang, Hu Jiangwei, Hu Guoliang, Ning Hongmei, Zhang Bin, Hu Liangding

Summary: This case report describes a patient with treated secondary AML who received tislelizumab in combination with azacitidine. While the patient achieved complete remission, they also experienced serious immune-related adverse events and graft vs. host disease, ultimately leading to death. This highlights the safety concerns of combining anti-PD-1 antibodies with azacitidine after allo-HSCT, particularly the risk of GVHD.

FRONTIERS IN IMMUNOLOGY (2021)

Add to Collection

Article Oncology

Interleukin-10-592 polymorphism: impact on relapse and survival after allogeneic hematopoietic stem cell transplantation in children with hematological malignancies

Laura Schwenk, Susan Wittig, Bernd Gruhn

Summary: The study revealed that the IL-10-592 CC genotype in the donor significantly reduces the relapse rate after hematopoietic stem cell transplantation, leading to an increase in event-free survival and overall survival.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2022)

Add to Collection

Letter Hematology

Decreased serum phosphate levels are a useful biomarker to predict occurrence and severity of cytokine release syndrome in chimeric antigen receptor T-cell therapy

Naokazu Nakamura, Yasuyuki Arai, Toshio Kitawaki, Tomoyasu Jo, Chisaki Mizumoto, Junya Kanda, Momoko Nishikori, Kouhei Yamashita, Akifumi Takaori-Kondo

BRITISH JOURNAL OF HAEMATOLOGY (2023)

Add to Collection

Article Cell & Tissue Engineering

Adverse effect of donor-specific anti-human leukocyte antigen (HLA) antibodies directed at HLA-DP/-DQ on engraftment in cord blood transplantation

Tomoyasu Jo, Yasuyuki Arai, Kazuo Hatanaka, Hiroyuki Ishii, Akiko Ono, Nobuki Matsuyama, Jumpei Mori, Yangsook Koh, Fumihiro Azuma, Takafumi Kimura

Summary: This study examined the impact of anti-HLA antibodies against HLA-DP and -DQ on cord-blood transplantation outcomes. The presence of DSAs against HLA-DP and -DQ was associated with lower engraftment rates, longer engraftment time, increased risk of bacterial infection, and reduced survival after transplantation.

CYTOTHERAPY (2023)

Add to Collection

Article Hematology

CMV reactivation after allogeneic HCT is associated with a reduced risk of relapse in acute lymphoblastic leukemia

Yu Akahoshi, Hideki Nakasone, Katsuto Takenaka, Satoshi Yamasaki, Momoko Nakamura, Noriko Doki, Masatsugu Tanaka, Yukiyasu Ozawa, Naoyuki Uchida, Takahide Ara, Hirohisa Nakamae, Shuichi Ota, Makoto Onizuka, Shingo Yano, Junji Tanaka, Takahiro Fukuda, Yoshinobu Kanda, Yoshiko Atsuta, Shinichi Kako, Masamitsu Yanada, Yasuyuki Arai

Summary: A nationwide retrospective study revealed that cytomegalovirus reactivation (CMVR) is associated with a lower relapse risk in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) patients after allogeneic hematopoietic cell transplantation (HCT). This finding suggests important implications for CMV prophylaxis strategies after HCT.

BLOOD ADVANCES (2023)

Add to Collection

Article Hematology

Effects of combined test dose and therapeutic drug monitoring strategy in exposure-directed busulfan

Tomoki Iemura, Tadakazu Kondo, Atsushi Ueda, Takeshi Maeda, Toshio Kitawaki, Yasuyuki Arai, Junya Kanda, Takashi Ikeda, Kazunori Imada, Takayuki Ishikawa, Naoyuki Anzai, Mitsuru Itoh, Tomoharu Takeoka, Takashi Akasaka, Kazuhiro Yago, Akihito Yonezawa, Nobuyoshi Arima, Toshiyuki Kitano, Masaharu Nohgawa, Mitsumasa Watanabe, Toshinori Moriguchi, Kouhei Yamashita, Yasunori Ueda, Kana Matsumoto, Akifumi Takaori-Kondo

Summary: Although exposure-directed busulfan (BU) dosing can improve transplantation outcomes, there is still large variability in BU exposure with test dose alone. We conducted a trial comparing a combined test dose and therapeutic drug monitoring strategy with a fixed-dose group. The combined strategy effectively controlled BU exposure and showed favorable outcomes in patients receiving FLU-containing regimen.

ANNALS OF HEMATOLOGY (2023)

Add to Collection

Article Hematology

Unrelated hematopoietic stem cell transplantation for familial platelet disorder/acute myeloid leukemia with germline RUNX1 mutations

Kazunori Toratani, Mizuki Watanabe, Junya Kanda, Tomomi Oka, Mizuki Hyuga, Yasuyuki Arai, Makoto Iwasaki, Maki Sakurada, Yasuhito Nannya, Seishi Ogawa, Takahiro Yamada, Akifumi Takaori-Kondo

Summary: This study presents two pedigrees, one diagnosed with familial platelet disorder with predisposition to acute myeloid leukemia (FPD/AML) molecularly and another highly suspected. Both pedigrees showed a family history of thrombocytopenia, platelet dysfunction, and hematological malignancies, highlighting the importance of searching for gene mutations associated with germline predisposition.

INTERNATIONAL JOURNAL OF HEMATOLOGY (2023)

Add to Collection

Review Rheumatology

Other iatrogenic immunodeficiency-associated lymphoproliferative disorders in a patient with anti-melanoma differentiation-associated gene 5-positive dermatomyositis: A case report and systematic literature review

Nozomi Nishimura, Takafumi Niwamoto, Yasuyuki Arai, Ran Nakashima, Kazuhiro Terada, Akihiko Yoshizawa, Ryo Sakamoto, Kiminobu Tanizawa, Tomohiro Handa, Akio Morinobu, Toyohiro Hirai

Summary: A 58-year-old man with MDA5-DM developed EBV-associated malignant lymphoma during immunosuppressive therapy. EBV reactivation played a role in the pathogenesis of LPD in this case. Prompt chemotherapy and discontinuation of immunosuppressants resulted in complete remission. This is the first reported case of MDA5-DM complicated with OIIA-LPD. Among 19 similar cases, regression of LPD occurred with withdrawal of immunosuppressants in 7 patients, chemotherapy was required in 9 patients, and 5 patients died.

INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES (2023)

Add to Collection

Article Hematology

Poor outcome of allogeneic transplantation for therapy-related acute myeloid leukemia induced by prior chemoradiotherapy

Hiroaki Araie, Yasuyuki Arai, Michiko Kida, Jun Aoki, Naoyuki Uchida, Noriko Doki, Takahiro Fukuda, Masatsugu Tanaka, Yukiyasu Ozawa, Masashi Sawa, Yuta Katayama, Yayoi Matsuo, Makoto Onizuka, Yoshinobu Kanda, Toshiro Kawakita, Junya Kanda, Yoshiko Atsuta, Masamitsu Yanada

Summary: Therapy-related acute myeloid leukemia (t-AML) is a late complication of chemotherapy (CHT) and/or radiotherapy (RT) for primary malignancy. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a curative approach for t-AML. This study evaluates the relationship between characteristics of primary malignancy and allo-HSCT outcomes to establish the optimal strategy.

ANNALS OF HEMATOLOGY (2023)

Add to Collection

Article Hematology

Advantages of Higher Busulfan Dose Intensity in Fludarabine-Combined Conditioning for Patients with Acute Myeloid Leukemia Undergoing Cord Blood Transplantation

Sho Shibata, Yasuyuki Arai, Tadakazu Kondo, Shohei Mizuno, Kaito Harada, Shigesaburo Miyakoshi, Naoyuki Uchida, Yumiko Maruyama, Tetsuya Eto, Yuna Katsuoka, Kosei Matsue, Kaichi Nishiwaki, Satoru Takada, Noriko Doki, Mitsuru Itoh, Koji Nagafuji, Toshiro Kawakita, Junji Tanaka, Takahiro Fukuda, Yoshiko Atsuta, Masamitsu Yanada

Summary: This study analyzed the outcomes of cord blood transplantation with busulfan conditioning in patients with acute myeloid leukemia. The results showed that higher doses of busulfan significantly improved disease-free survival and reduced relapse rate. This is particularly important for patients not in complete remission and younger patients.

TRANSPLANTATION AND CELLULAR THERAPY (2023)

Add to Collection

Correction Medicine, Research & Experimental

A convolutional neural network-based model that predicts acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation (vol 3, 67, 2023)

Tomoyasu Jo, Yasuyuki Arai, Junya Kanda, Tadakazu Kondo, Kazuhiro Ikegame, Naoyuki Uchida, Noriko Doki, Takahiro Fukuda, Yukiyasu Ozawa, Masatsugu Tanaka, Takahide Ara, Takuro Kuriyama, Yuta Katayama, Toshiro Kawakita, Yoshinobu Kanda, Makoto Onizuka, Tatsuo Ichinohe, Yoshiko Atsuta, Seitaro Terakura

COMMUNICATIONS MEDICINE (2023)

Add to Collection

Article Medicine, Research & Experimental

A convolutional neural network-based model that predicts acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation

Tomoyasu Jo, Yasuyuki Arai, Junya Kanda, Tadakazu Kondo, Kazuhiro Ikegame, Naoyuki Uchida, Noriko Doki, Takahiro Fukuda, Yukiyasu Ozawa, Masatsugu Tanaka, Takahide Ara, Takuro Kuriyama, Yuta Katayama, Toshiro Kawakita, Yoshinobu Kanda, Makoto Onizuka, Tatsuo Ichinohe, Yoshiko Atsuta, Seitaro Terakura

Summary: This study establishes a convolutional neural network-based model to predict acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic stem cell transplantation. The model predicts the risk of aGVHD and identifies the impact of pre-transplant parameters on the risk of aGVHD.

COMMUNICATIONS MEDICINE (2023)

Add to Collection

Article Hematology

Significance of Omitting Day 11 Mini-Dose Methotrexate for GVHD Prophylaxis After Unrelated Bone Marrow Transplantation

Naokazu Nakamura, Fumiya Wada, Tadakazu Kondo, Kazunari Aoki, Yasuyuki Arai, Chisaki Mizumoto, Junya Kanda, Toshio Kitawaki, Kouhei Yamashita, Akifumi Takaori-Kondo

Summary: The combination of calcineurin inhibitors and short-term methotrexate is a standard prophylaxis for graft-versus-host disease (GVHD) in allogeneic hematopoietic stem cell transplantation. However, the omission of the day 11 methotrexate dose is associated with a higher risk of severe GVHD.

TRANSPLANTATION AND CELLULAR THERAPY (2023)

Add to Collection

Article Hematology

Belt Electrode-Skeletal Muscle Electrical Stimulation During Early Hematopoietic Post-Transplantation To Prevent Skeletal Muscle Atrophy and Weakness

Ryota Hamada, Susumu Sato, Junsuke Miyasaka, Masanobu Murao, Michiko Matsushita, Taishi Kajimoto, Ayumi Otagaki, Tsugumi Asano, Manabu Nankaku, Tadakazu Kondo, Yasuyuki Arai, Junya Kanda, Akifumi Takaori-Kondo, Ryosuke Ikeguchi, Shuichi Matsuda

Summary: This study examined the effect of B-SES on physical function and safety in patients during the early post-transplantation period. The results showed that B-SES can significantly improve muscle strength and walking distance in patients, with better outcomes in the high-intensity stimulation group.

TRANSPLANTATION AND CELLULAR THERAPY (2023)

Add to Collection

Letter Biophysics

KyoTox-e score; prediction of post-CAR-T prolonged thrombocytopenia using peripheral blood data before apheresis

Tomoyasu Jo, Yasuyuki Arai, Toshio Kitawaki, Naokazu Nakamura, Momoko Nishikori, Chisaki Mizumoto, Junya Kanda, Kouhei Yamashita, Miki Nagao, Akifumi Takaori-Kondo

BONE MARROW TRANSPLANTATION (2023)

Add to Collection

Article Hematology

Impact of Antimicrobial Drug-Drug Interactions on Acute Kidney Injury after Allogeneic Hematopoietic Cell Transplantation

Fumiya Wada, Yasuyuki Arai, Tomoyasu Jo, Chisaki Mizumoto, Junya Kanda, Toshio Kitawaki, Momoko Nishikori, Kouhei Yamashita, Akifumi Takaori-Kondo

Summary: Drug-drug interactions (DDIs) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) are a major cause of acute kidney injury (AKI). This retrospective analysis of 465 allo-HSCTs in 416 patients found that AKI was significantly associated with reduced overall survival and increased transplantation-related mortality. The use of ciprofloxacin, cefepime, tazobactam/piperacillin, meropenem, vancomycin, liposomal amphotericin B, ganciclovir, and foscarnet significantly increased the incidence of AKI, and specific combinations of drugs synergistically increased the risk of AKI. These findings highlight the importance of avoiding certain drug combinations to preserve renal function and reduce AKI-related morbidity and mortality.

TRANSPLANTATION AND CELLULAR THERAPY (2023)

Add to Collection

Article Immunology

Activation of nucleotide-binding oligomerization domain 2 by muramyl dipeptide negatively regulates Toll-like receptor 9-mediated colonic inflammation through the induction of deubiquitinating enzyme A expression

Yasuhiro Masuta, Kosuke Minaga, Masayuki Kurimoto, Ikue Sekai, Akane Hara, Naoya Omaru, Natsuki Okai, Yasuo Otsuka, Ryutaro Takada, Tomoe Yoshikawa, Sho Masaki, Ken Kamata, Hajime Honjo, Yasuyuki Arai, Kouhei Yamashita, Masatoshi Kudo, Tomohiro Watanabe

Summary: This study found that NOD2 activation reduces TLR9-induced IFN-alpha production through DUBA. Activation of NOD2 in hematopoietic cells can protect mice from TLR9-induced exacerbation of DSS-induced colitis. The expression of IFN-alpha and ISGs in colonic mucosa is associated with the active and remitted phases of inflammatory bowel disease.

INTERNATIONAL IMMUNOLOGY (2023)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.